ImpactRx gobbles up TargetRx

Share this article:

ImpactRx, which measures the impact of promotion on prescriber behavior, said it acquired 100% of TargetRx, a pharma sales and marketing effectiveness firm. 

Terms were not disclosed, but a source familiar with the transaction estimated its size at $5-10 million.

Known as ImpactRx, the combined company will be led by new ImpactRx president and CEO Gregory Ellis, who recently replaced Richard Altus in that role. (See p. 55 for a profile.)

Since 1999, TargetRx has been providing pharma and biotech companies with insight into the drivers of both product choice and brand adoption. But it had struggled in the last year from customer and employee turnover. 

ImpactRx is part of private equity firm Symphony Technology Group, which in April acquired a majority interest for an undisclosed sum. Merck Capital Ventures, the venture capital arm of Merck, also maintains a stake.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.